TY - JOUR
T1 - Cardiac dysfunction in cancer patients
T2 - beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
AU - Tocchetti, Carlo Gabriele
AU - Ameri, Pietro
AU - de Boer, Rudolf A.
AU - D'Alessandra, Yuri
AU - Russo, Michele
AU - Sorriento, Daniela
AU - Ciccarelli, Michele
AU - Kiss, Bernadett
AU - Bertrand, Luc
AU - Dawson, Dana
AU - Falcao-Pires, Ines
AU - Giacca, Mauro
AU - Hamdani, Nazha
AU - Linke, Wolfgang A.
AU - Mayr, Manuel
AU - van der Velden, Jolanda
AU - Zacchigna, Serena
AU - Ghigo, Alessandra
AU - Hirsch, Emilio
AU - Lyon, Alexander R.
AU - Görbe, Anikó
AU - Ferdinandy, Péter
AU - Madonna, Rosalinda
AU - Heymans, Stephane
AU - Thum, Thomas
PY - 2020/9/1
Y1 - 2020/9/1
N2 - In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.
AB - In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.
KW - Cardio-Oncology
KW - Common pathways in heart failure and cancer
KW - Multicellular
KW - Multiorgan mechanisms
UR - http://www.scopus.com/inward/record.url?scp=85088271730&partnerID=8YFLogxK
U2 - 10.1093/cvr/cvaa222
DO - 10.1093/cvr/cvaa222
M3 - Article
C2 - 32683451
AN - SCOPUS:85088271730
SN - 0008-6363
VL - 116
SP - 1820
EP - 1834
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 11
ER -
